Coeptis Therapeutics (COEP) News Today $0.19 0.00 (-1.91%) (As of 11:50 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical DevelopmentNovember 7, 2024 | prnewswire.comCoeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency UseOctober 24, 2024 | prnewswire.comCoeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell TherapyOctober 15, 2024 | prnewswire.comCoeptis Therapeutics (NASDAQ:COEP) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comCoeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingSeptember 19, 2024 | prnewswire.comCoeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to ShareholdersSeptember 5, 2024 | prnewswire.comCOEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024August 16, 2024 | investorplace.comCoeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingJune 20, 2024 | prnewswire.comCoeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingMay 30, 2024 | prnewswire.comCOEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024May 13, 2024 | msn.comCoeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024May 8, 2024 | prnewswire.comCoeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingMay 2, 2024 | prnewswire.comDeverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid LeukemiaApril 24, 2024 | finance.yahoo.comCoeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardApril 2, 2024 | prnewswire.comCOEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023April 1, 2024 | investorplace.comCoeptis expands license for CAR technology to autoimmune diseasesFebruary 28, 2024 | investing.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 26, 2024 | finance.yahoo.comCoeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKFebruary 26, 2024 | prnewswire.comCoeptis Therapeutics Holdings Inc Ordinary Shares COEPFebruary 17, 2024 | morningstar.comCoeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsFebruary 7, 2024 | finance.yahoo.comCoeptis Therapeutics Risks Nasdaq Delisting Over Bid PriceFebruary 2, 2024 | msn.comThese are the 4 hottest stocks insiders bought in JanuaryJanuary 29, 2024 | insidertrades.comCoeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024January 4, 2024 | finance.yahoo.comCoeptis Therapeutics Stock (NASDAQ:COEP) Insider TradesDecember 9, 2023 | benzinga.comCoeptis Therapeutics to Present at the Emerging Growth ConferenceDecember 4, 2023 | finance.yahoo.comBuy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing AssetsNovember 15, 2023 | markets.businessinsider.comCoeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023October 31, 2023 | finance.yahoo.comCoeptis Therapeutics to raise $2M in a private placementOctober 24, 2023 | msn.comCoeptis Therapeutics Announces $2 Million Private PlacementOctober 24, 2023 | finance.yahoo.comLocal pharma firm widens technology deal with the University of PittsburghOctober 11, 2023 | bizjournals.comCoeptis Expands License Agreement With University Of Pittsburgh To Include SNAP-CAR PlatformOctober 11, 2023 | markets.businessinsider.comCoeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesOctober 9, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingOctober 4, 2023 | finance.yahoo.comCoeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaSeptember 27, 2023 | finance.yahoo.comSeattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapiesSeptember 20, 2023 | msn.comCoeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionSeptember 14, 2023 | finance.yahoo.comCoeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentSeptember 11, 2023 | finance.yahoo.comCoeptis appoints Colleen Delaney as chief scientific and medical officerSeptember 5, 2023 | bizjournals.comCoeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerAugust 30, 2023 | finance.yahoo.comCoeptics Flat on Deverra DealAugust 17, 2023 | baystreet.caCoeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsAugust 17, 2023 | finance.yahoo.comCoeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticAugust 1, 2023 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Clearside Biomedical (CLSD)July 21, 2023 | markets.businessinsider.comCoeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingJune 16, 2023 | finance.yahoo.comCoeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten OfferingJune 14, 2023 | benzinga.comCoeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingJune 14, 2023 | finance.yahoo.comEF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)June 12, 2023 | markets.businessinsider.comCoeptis Therapeutics to join Nasdaq Capital Market next MondayJune 9, 2023 | bizjournals.comCoeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketJune 9, 2023 | finance.yahoo.comCoeptis Therapeutics Shares Rally 67% In May, Clinical Interests And Planned Acquisitions Attract The Interest ($COEP)May 30, 2023 | benzinga.com Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here COEP Media Mentions By Week COEP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COEP News Sentiment▼0.000.47▲Average Medical News Sentiment COEP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COEP Articles This Week▼00▲COEP Articles Average Week Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ensysce Biosciences News LianBio News Lantern Pharma News Citius Pharmaceuticals News HCW Biologics News Surrozen News BioVie News KALA BIO News BioLineRx News Daré Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COEP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COEP Stock Alerts